speaker-icon

Latest Posts

Partex-Group-presents-results-from-a-pilot-project-with-AIO

18

Mar 24

Innovative AI technology in oncology: Partex Group presents results from a pilot project

During the German Cancer Congress 2024 in Berlin, the companies Innoplexus AG /Amrit AG, companies of Partex N.V., presented the...
Read More
Partex-Sanofi-press-release-illustration

14

Mar 24

Partex NV Forges Collaboration with Sanofi in AI-Based Dossier Enrichment for Out-Licensing

Frankfurt, Germany; 14 March 2024 Partex Group, a pioneer in AI-driven drug discovery, today announces a collaboration with global pharmaceutical...
Read More

Innoplexus wins Horizon Interactive Gold Award for Curia App

Read More
blockchain

Blockchain and AI-based Platform iPlexus to Revolutionize Drug Discovery

Innoplexus AG announced a revolutionary update is coming soon to their iPlexus platform that will harness the power of blockchain technology and artificial intelligence to weed out wastefulness in early-stage drug discovery. iPlexus is a one-stop deep data ocean of relevant information for the pharmaceutical industry. It uses the power of Blockchain and AI to revolutionize the drug discovery and research process.

Co-founder and CEO of Innoplexus AG, Gunjan Bhardwaj, explained more about their vision for the new iPlexus, “Our mission at Innoplexus is to democratize the drug discovery process. We believe that cutting-edge technologies like AI and blockchain are the key to making this possible. After over 6 months of research, we believe that the new iPlexus is a major step forward for the preclinical trial industry and will solve many of the problems that are slowing the industry down. By overcoming these challenges, we will make drug discovery more efficient and bring down the consumer price of drugs.”

The launch date is scheduled for June 30, 2018. Blockchain and AI-based iPlexus intends to overcome data silos to make drug discovery more efficient. iPlexus will help in intelligence and insights throughout pre-clinical, clinical, regulatory and commercial phases of drug development in a quick, crisp and summarized snapshot with various profound dive opportunities.

The platform has the potential to bolster the healthcare system through practical innovation acceleration and equal opportunities. It would incentivize smaller researchers to share even failed experimental data. Data enrichment would, in turn, lead to data innovation and the innovation dynamics would be beneficial for the patients.

The original article was published on BCFocus.

Featured News

new_app_cancer_patients

New app for cancer patients

Das Eschborner Unternehmen Innoplexus hat eine neue App namens „Curia“ für Krebspatienten veröffentlicht. Mit dem Computerprogramm, das sich unentgeltlich herunterladen…